Syndax Pharmaceuticals SNDX Investment Proceeds
Investment Proceeds at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.
The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Syndax Pharmaceuticals's investment proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Syndax Pharmaceuticals's investment proceeds?
- Syndax Pharmaceuticals (SNDX) reported investment proceeds of $77.78M in Q1 2026.
- How has Syndax Pharmaceuticals's investment proceeds changed year-over-year?
- Syndax Pharmaceuticals's investment proceeds decreased by 25.7% year-over-year, from $104.68M to $77.78M.
- What is the long-term trend for Syndax Pharmaceuticals's investment proceeds?
- Over 4 years (2021 to 2025), Syndax Pharmaceuticals's investment proceeds has grown at a 17.6% compound annual growth rate (CAGR), from $253.98M to $486.03M.
- What does investment proceeds mean?
- Cash received from sales, maturities, and redemptions of investment securities across all categories.